Jie Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jie Zhang has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
Junjiao Ping
Department of Psychiatry The Third People's Hospital of Zhongshan City Zhongshan Guangdong China
4 shared publicationsTingyun Jiang
Department of Psychiatry The Third People's Hospital of Zhongshan City Zhongshan Guangdong China
4 shared publicationsJiali Luo
Department of Psychiatry, The Third People’s Hospital of Zhongshan, 528451 Zhongshan, Guangdong, China
3 shared publicationsJing Wan
Department of Early Intervention The Third People's Hospital of Zhongshan City Zhongshan Guangdong China
3 shared publicationsBaoguo Du
Department of Clinical Psychology The Third People's Hospital of Zhongshan City Zhongshan China
2 shared publications- Tingyun Jiang
Department of Psychiatry, The Third People’s Hospital of Zhongshan, 528451 Zhongshan, Guangdong, China
2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-11
Prevalence and Clinical Correlates of Anxiety in Chinese Outpatient Population with Somatic Symptom Disorder
Background: Anxiety is highly prevalent among patients with Somatic Symptom Disorder (SSD) and is strongly associated with adverse outcomes. However, its associated factors remain largely unexplored. This study aimed to investigate the incidence of anxiety and its related factors in patients with SSD. Methods: A total of 899 patients with SSD were recruited. Anxiety levels were assessed using the 17-item Hamilton Anxiety scale (HAMA-17). Clinical features, including depressive and psychiatric symptoms, were measured alongside physiological measures, such as fasting blood glucose, blood pressure, lipid profiles, and thyroid levels. Binary logistic regression models were used to identify independent correlates of anxiety. Results: The prevalence of anxiety symptoms in Chinese patients with SSD is 67.41%. Compared to patients without anxiety, patients with anxiety symptoms had higher Hamilton Depression (HAMD) score, higher suicide attempt rate, psychotic symptoms, and higher levels of some physiological indicators. Binary logistic analysis indicated that HAMD score, suicide attempts, antithyroglobulin (A-TG), and diastolic blood pressure (DP) levels were correlated with anxiety symptoms in patients with SSD. Conclusion: This study highlights the high prevalence of anxiety in patients with SSD. Anxiety is associated with depression, suicide attempts, A-TG, and DP levels in patients with SSD. While causality cannot be established due to the cross-sectional design, these findings highlight potential clinical markers that may help identify patients at higher risk of anxiety and provide a basis for future longitudinal studies to explore underlying mechanisms.
- 1 January 2026
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 22, 1-11
Open AccessPrevalence and Clinical Correlates of Anxiety in Chinese Outpatient Population with Somatic Symptom Disorder
Background: Anxiety is highly prevalent among patients with Somatic Symptom Disorder (SSD) and is strongly associated with adverse outcomes. However, its associated factors remain largely unexplored. This study aimed to investigate the incidence of anxiety and its related factors in patients with SSD. Methods: A total of 899 patients with SSD were recruited. Anxiety levels were assessed using the 17-item Hamilton Anxiety scale (HAMA-17). Clinical features, including depressive and psychiatric symptoms, were measured alongside physiological measures, such as fasting blood glucose, blood pressure, lipid profiles, and thyroid levels. Binary logistic regression models were used to identify independent correlates of anxiety. Results: The prevalence of anxiety symptoms in Chinese patients with SSD is 67.41%. Compared to patients without anxiety, patients with anxiety symptoms had higher Hamilton Depression (HAMD) score, higher suicide attempt rate, psychotic symptoms, and higher levels of some physiological indicators. Binary logistic analysis indicated that HAMD score, suicide attempts, antithyroglobulin (A-TG), and diastolic blood pressure (DP) levels were correlated with anxiety symptoms in patients with SSD. Conclusion: This study highlights the high prevalence of anxiety in patients with SSD. Anxiety is associated with depression, suicide attempts, A-TG, and DP levels in patients with SSD. While causality cannot be established due to the cross-sectional design, these findings highlight potential clinical markers that may help identify patients at higher risk of anxiety and provide a basis for future longitudinal studies to explore underlying mechanisms.
- 22 June 2025
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 85 (4) , e70027
Association of Serum SOCS3 and Inflammatory Marker Levels With Cognitive Function in First‐Episode Schizophrenia
Background: Accumulating evidence suggests that dysregulated inflammatory signalling pathway plays a crucial role in the development and pathogenesis of clinical features in schizophrenia. SOCS3, a key regulator of inflammatory signalling pathways, has been implicated in this process. However, the complicated association between SOCS3 function and clinical features in unmedicated first‐episode schizophrenia (SCZ) remains poorly understood. While increased levels of systemic inflammatory markers, including C‐reactive protein (CRP) and proinflammatory cytokines like IL‐6 and IL‐1β, have been negatively linked to severity of negative and mood symptoms in SCZ patients, the levels of systemic inflammatory markers cytokines levels neurocognitive function in SCZ warrants further investigation. The primary hypotheses of this study are as follows: (1) The levels of SOCS3 and systemic inflammatory cytokines levels could differentiate between individuals with first‐episode SCZ and healthy controls. (2) Patients with first‐episode SCZ exhibit significantly lower cognitive function and executive abilities compared to healthy controls. (3) Dysregulated SOCS3 pathways contribute to cognitive impairment in first‐episode SCZ.Methods: A total of 93 patients diagnosed with first‐episode SCZ and 60 healthy controls were recruited for the current study. The serum levels of CRP, IL‐6, IL‐1β and SOCS3 were determined with ELISA. Clinical symptoms in SCZ patients were evaluated using the PANSS scale and Stroop test, while cognitive function in the healthy control group were assessed solely using the Stroop test. Statistical analyses were performed with adjustments for age and gender as covariates.Results: Compared to healthy controls, individuals with first‐episode SCZ exhibited significantly decreased serum SOCS3 levels (p < 0.05) and elevated IL‐6 levels (p < 0.05), while no significant differences in CRP or IL‐1β levels (p > 0.05) were observed between the two groups. In the Stroop test, the SCZ group demonstrated prolonged response times (One word time, One colour time, word‐Color time and Color‐Word time) and increased error rates (One word errors, One colour errors, Word‐Colour errors and Colour‐Word errors) compared to healthy controls, with all differences reaching statistical significance (p < 0.05). Serum SOCS3 levels were negatively correlated with PANSS cognitive subscale scores in the SCZ group, whereas IL‐6 levels showed a positive correlation with one‐colour time and one‐colour errors in the Stroop test. The predictive value of serum SOCS3 for SCZ was determined by an AUC of 0.832, surpassing that of IL‐6 (AUC = 0.789).Conclusion: The current findings along with previous studies support the immune dysfunction plays a potential role in development of SCZ. Notably, alteration in peripheral levels of SOCS3 and IL‐6 highlighting their potential application for early intervention for first episode SCZ and these changes are further associated with cognitive dysfunction. Moreover, SOCS3 demonstrated superior sensitivity in predicting SCZ, underscoring the importance of further investigating its role in SCZ pathogenesis and exploring novel therapeutic interventions.
- 22 June 2025
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 85 (4) , e70027
Association of Serum SOCS3 and Inflammatory Marker Levels With Cognitive Function in First‐Episode Schizophrenia
Background: Accumulating evidence suggests that dysregulated inflammatory signalling pathway plays a crucial role in the development and pathogenesis of clinical features in schizophrenia. SOCS3, a key regulator of inflammatory signalling pathways, has been implicated in this process. However, the complicated association between SOCS3 function and clinical features in unmedicated first‐episode schizophrenia (SCZ) remains poorly understood. While increased levels of systemic inflammatory markers, including C‐reactive protein (CRP) and proinflammatory cytokines like IL‐6 and IL‐1β, have been negatively linked to severity of negative and mood symptoms in SCZ patients, the levels of systemic inflammatory markers cytokines levels neurocognitive function in SCZ warrants further investigation. The primary hypotheses of this study are as follows: (1) The levels of SOCS3 and systemic inflammatory cytokines levels could differentiate between individuals with first‐episode SCZ and healthy controls. (2) Patients with first‐episode SCZ exhibit significantly lower cognitive function and executive abilities compared to healthy controls. (3) Dysregulated SOCS3 pathways contribute to cognitive impairment in first‐episode SCZ.Methods: A total of 93 patients diagnosed with first‐episode SCZ and 60 healthy controls were recruited for the current study. The serum levels of CRP, IL‐6, IL‐1β and SOCS3 were determined with ELISA. Clinical symptoms in SCZ patients were evaluated using the PANSS scale and Stroop test, while cognitive function in the healthy control group were assessed solely using the Stroop test. Statistical analyses were performed with adjustments for age and gender as covariates.Results: Compared to healthy controls, individuals with first‐episode SCZ exhibited significantly decreased serum SOCS3 levels (p < 0.05) and elevated IL‐6 levels (p < 0.05), while no significant differences in CRP or IL‐1β levels (p > 0.05) were observed between the two groups. In the Stroop test, the SCZ group demonstrated prolonged response times (One word time, One colour time, word‐Color time and Color‐Word time) and increased error rates (One word errors, One colour errors, Word‐Colour errors and Colour‐Word errors) compared to healthy controls, with all differences reaching statistical significance (p < 0.05). Serum SOCS3 levels were negatively correlated with PANSS cognitive subscale scores in the SCZ group, whereas IL‐6 levels showed a positive correlation with one‐colour time and one‐colour errors in the Stroop test. The predictive value of serum SOCS3 for SCZ was determined by an AUC of 0.832, surpassing that of IL‐6 (AUC = 0.789).Conclusion: The current findings along with previous studies support the immune dysfunction plays a potential role in development of SCZ. Notably, alteration in peripheral levels of SOCS3 and IL‐6 highlighting their potential application for early intervention for first episode SCZ and these changes are further associated with cognitive dysfunction. Moreover, SOCS3 demonstrated superior sensitivity in predicting SCZ, underscoring the importance of further investigating its role in SCZ pathogenesis and exploring novel therapeutic interventions.
- Open Access
- 28 February 2025
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 26 (1) , 38788
Prevalence and Correlates of Depressive Symptoms and Cognitive Impairment in Elderly People over 65 Years Old in the Community and Nursing Homes
Objective: Cognitive impairment and depression significantly reduce quality of life in the aging population. This study aimed to investigate the prevalence of depressive symptoms and cognitive impairment and explore its relationship in the elderly. Methods: A total of 1645 elderly people in nursing homes and 4703 elderly people in the community were enrolled in the survey. The Patient Health Questionnaire-9 and Ascertain Dementia-8 were employed to evaluate depressive symptoms and cognitive impairment. Results: The overall prevalence of cognitive impairment was 12.5% in the community-dwelling group and 52.2% in the nursing home group. The prevalence of cognitive impairment in nursing homes was significantly higher than that in community-dwelling groups for the same age group (p < 0.001). The overall prevalence of depressive symptoms was 3.9% in the community-dwelling group and 2.0% in the nursing home group. The prevalence of depressive symptoms increased with age in the community-dwelling group (p < 0.001). The binary logistic regression results showed that the type of care mode affected the prevalence of cognitive impairment, and the elderly in nursing homes had a high risk of cognitive impairment (odds ratio [OR] = 3.528, 95% confidence interval [CI]: 2.209–5.635, p < 0.001); depressive symptoms had a significant positive correlation with the odds of cognitive impairment (OR = 1.854, 95% CI: 1.052–3.266, p < 0.05); and the cognitive impairment rate increased with age (OR = 1.412, 95% CI: 1.044–1.910, p < 0.05). Conclusions: There was an increased prevalence in cognitive impairment as well as depressive symptoms in the aging population in Zhongshan city. Population-based mental health strategies need to be urgently implemented for the aging.
- 28 February 2025
- Published by IMR Press in ALPHA PSYCHIATRY
- Vol. 26 (1) , 38788
Open AccessPrevalence and Correlates of Depressive Symptoms and Cognitive Impairment in Elderly People over 65 Years Old in the Community and Nursing Homes
Objective: Cognitive impairment and depression significantly reduce quality of life in the aging population. This study aimed to investigate the prevalence of depressive symptoms and cognitive impairment and explore its relationship in the elderly. Methods: A total of 1645 elderly people in nursing homes and 4703 elderly people in the community were enrolled in the survey. The Patient Health Questionnaire-9 and Ascertain Dementia-8 were employed to evaluate depressive symptoms and cognitive impairment. Results: The overall prevalence of cognitive impairment was 12.5% in the community-dwelling group and 52.2% in the nursing home group. The prevalence of cognitive impairment in nursing homes was significantly higher than that in community-dwelling groups for the same age group (p < 0.001). The overall prevalence of depressive symptoms was 3.9% in the community-dwelling group and 2.0% in the nursing home group. The prevalence of depressive symptoms increased with age in the community-dwelling group (p < 0.001). The binary logistic regression results showed that the type of care mode affected the prevalence of cognitive impairment, and the elderly in nursing homes had a high risk of cognitive impairment (odds ratio [OR] = 3.528, 95% confidence interval [CI]: 2.209–5.635, p < 0.001); depressive symptoms had a significant positive correlation with the odds of cognitive impairment (OR = 1.854, 95% CI: 1.052–3.266, p < 0.05); and the cognitive impairment rate increased with age (OR = 1.412, 95% CI: 1.044–1.910, p < 0.05). Conclusions: There was an increased prevalence in cognitive impairment as well as depressive symptoms in the aging population in Zhongshan city. Population-based mental health strategies need to be urgently implemented for the aging.
- 31 January 2024
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 84 (2) , 154-159
The interaction of RELN–DNMT genes involving in neurotrophin signaling pathway contributes to schizophrenia susceptibility
Objective: Schizophrenia belongs to a severe mental illness with complicated clinical presentations, an ill‐defined pathogenesis, and no known cause. Many genetic studies imply that polygenic interaction is important in the development of schizophrenia. The main mechanism of the RELN‐BDNF‐CREB‐DNMT signaling pathway in neurodevelopment involves RELN, brain‐derived neurotrophic factor (BDNF), transcription factor cyclic adenosine monophosphate response element binding protein (CREB), DNA methyltransferase 1 (DNMT1), as well as DNA methyltransferase 3B (DNMT3B). An early case–control research on 15 polymorphisms in the RELN, CREB, BDNF, DNMT1, and DNMT3B genes was done. A single gene variation has little effect on the pathogenesis of schizophrenia, but the combination of intergenic variation loci has a bigger impact because schizophrenia is a complex polygenic disorder. The objective of the current study sought to explore the impact of genetic interactions between RELN, BDNF, CREB, DNMT1, and DNMT3B on schizophrenia in order to further highlight the genetic factors influencing the risk of schizophrenia.Methods: Taking the case–control study design, with the Diagnostic and Statistical Manual of Mental Disorders‐Fifth Edition (DSM‐5) to be the evaluation norm, 134 individuals suffering from schizophrenia hospitalized in the Third People's Hospital of Zhongshan City within January 2018 to April 2020 (case group) were selected, and 64 healthy individuals (control group) from the same geographical area had been chosen as well. MassArray identified DNMT1 gene single nucleotide polymorphisms (rs2114724 and rs2228611) and DNMT3B gene SNPs (rs2424932, rs1569686, rs6119954, and rs2424908). Using the generalized multifactor dimensionality reduction (GMDR), the RELN‐BDNF‐CREB‐DNMT pathway's gene interactions were examined for their impact on schizophrenia.Results: GMDR analysis showed that the three‐order interaction model RELN (rs2073559, rs2229864)–DNMT3B (rs2424908) was the optimal model (p = 0.001), with the consistency of cross‐validation of 10/10 and the test accuracy of 0.8711.Conclusion: The interaction between the RELN (rs2073559, rs2229864)–DNMT3B (rs2424908) may be related to schizophrenia, and large sample sizes should be verified in different population.
- 31 January 2024
- Published by Wiley in International Journal of Developmental Neuroscience
- Vol. 84 (2) , 154-159
The interaction of RELN–DNMT genes involving in neurotrophin signaling pathway contributes to schizophrenia susceptibility
Objective: Schizophrenia belongs to a severe mental illness with complicated clinical presentations, an ill‐defined pathogenesis, and no known cause. Many genetic studies imply that polygenic interaction is important in the development of schizophrenia. The main mechanism of the RELN‐BDNF‐CREB‐DNMT signaling pathway in neurodevelopment involves RELN, brain‐derived neurotrophic factor (BDNF), transcription factor cyclic adenosine monophosphate response element binding protein (CREB), DNA methyltransferase 1 (DNMT1), as well as DNA methyltransferase 3B (DNMT3B). An early case–control research on 15 polymorphisms in the RELN, CREB, BDNF, DNMT1, and DNMT3B genes was done. A single gene variation has little effect on the pathogenesis of schizophrenia, but the combination of intergenic variation loci has a bigger impact because schizophrenia is a complex polygenic disorder. The objective of the current study sought to explore the impact of genetic interactions between RELN, BDNF, CREB, DNMT1, and DNMT3B on schizophrenia in order to further highlight the genetic factors influencing the risk of schizophrenia.Methods: Taking the case–control study design, with the Diagnostic and Statistical Manual of Mental Disorders‐Fifth Edition (DSM‐5) to be the evaluation norm, 134 individuals suffering from schizophrenia hospitalized in the Third People's Hospital of Zhongshan City within January 2018 to April 2020 (case group) were selected, and 64 healthy individuals (control group) from the same geographical area had been chosen as well. MassArray identified DNMT1 gene single nucleotide polymorphisms (rs2114724 and rs2228611) and DNMT3B gene SNPs (rs2424932, rs1569686, rs6119954, and rs2424908). Using the generalized multifactor dimensionality reduction (GMDR), the RELN‐BDNF‐CREB‐DNMT pathway's gene interactions were examined for their impact on schizophrenia.Results: GMDR analysis showed that the three‐order interaction model RELN (rs2073559, rs2229864)–DNMT3B (rs2424908) was the optimal model (p = 0.001), with the consistency of cross‐validation of 10/10 and the test accuracy of 0.8711.Conclusion: The interaction between the RELN (rs2073559, rs2229864)–DNMT3B (rs2424908) may be related to schizophrenia, and large sample sizes should be verified in different population.
- Open Access
- 13 October 2023
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 22 (1) , 1-10
DNMT1 SNPs (rs2114724 and rs2228611) associated with positive symptoms in Chinese patients with schizophrenia
Schizophrenia is a serious mental disorder with complex clinical manifestations, while its pathophysiological mechanism is not fully understood. Accumulated evidence suggested the alteration in epigenetic pathway was associated with clinical features and brain dysfunctions in schizophrenia. DNA methyltransferases (DNMTs), a key enzyme for DNA methylation, are related to the development of schizophrenia, whereas the current research evidence is not sufficient. The aim of study was to explore the effects of gene polymorphisms of DNMTs on the susceptibility and symptoms of schizophrenia. The study was case–control study that designed and employed the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) as the diagnostic standard. 134 hospitalized patients with schizophrenia in the Third People's Hospital of Zhongshan City from January 2018 to April 2020 (Case group) as well as 64 healthy controls (Control group) from the same region were involved. Single nucleotide polymorphisms (SNPs) of DNMT1 genes (r s2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) were determined with massARRAY. Linkage disequilibrium analysis and haplotype analysis were performed, and genotype and allele frequencies were compared. The Hardy–Weinberg equilibrium was tested by the Chi-square test in SPSS software (version 20.0, SPSS Inc., USA). The severity of clinical symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS). The correlation between DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs2424932, rs1569686, rs6119954 and rs2424908) and clinical features was analyzed. There were no significant differences in genotype, allele frequency and haplotype of DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) between the case and healthy control group. There were significant differences in the PANSS total positive symptom scores, P3 (hallucinatory behavior), P6 (suspicious/persecution), G7 (motor retardation), and G15 (preoccupation) in patients with different DNMT1 gene rs 2114724 and rs 2228611 genotypes. The linkage disequilibrium analysis of gene polymorphic loci revealed that rs 2114724–rs 2228611 was complete linkage disequilibrium, and rs 1569686–rs 2424908, rs 2424932–rs 1569696 and rs 2424932–rs 2424908 were strongly linkage disequilibrium. The polymorphisms alteration in genetic pathway may be associated with development of specific clinical features in schizophrenia.
- 13 October 2023
- Published by Springer Nature in Annals of General Psychiatry
- Vol. 22 (1) , 1-10
Open AccessDNMT1 SNPs (rs2114724 and rs2228611) associated with positive symptoms in Chinese patients with schizophrenia
Schizophrenia is a serious mental disorder with complex clinical manifestations, while its pathophysiological mechanism is not fully understood. Accumulated evidence suggested the alteration in epigenetic pathway was associated with clinical features and brain dysfunctions in schizophrenia. DNA methyltransferases (DNMTs), a key enzyme for DNA methylation, are related to the development of schizophrenia, whereas the current research evidence is not sufficient. The aim of study was to explore the effects of gene polymorphisms of DNMTs on the susceptibility and symptoms of schizophrenia. The study was case–control study that designed and employed the Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) as the diagnostic standard. 134 hospitalized patients with schizophrenia in the Third People's Hospital of Zhongshan City from January 2018 to April 2020 (Case group) as well as 64 healthy controls (Control group) from the same region were involved. Single nucleotide polymorphisms (SNPs) of DNMT1 genes (r s2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) were determined with massARRAY. Linkage disequilibrium analysis and haplotype analysis were performed, and genotype and allele frequencies were compared. The Hardy–Weinberg equilibrium was tested by the Chi-square test in SPSS software (version 20.0, SPSS Inc., USA). The severity of clinical symptoms was assessed by the Positive and Negative Syndrome Scale (PANSS). The correlation between DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs2424932, rs1569686, rs6119954 and rs2424908) and clinical features was analyzed. There were no significant differences in genotype, allele frequency and haplotype of DNMT1 genes (rs 2114724 and rs 2228611) and DNMT3B genes (rs 2424932, rs 1569686, rs 6119954 and rs 2424908) between the case and healthy control group. There were significant differences in the PANSS total positive symptom scores, P3 (hallucinatory behavior), P6 (suspicious/persecution), G7 (motor retardation), and G15 (preoccupation) in patients with different DNMT1 gene rs 2114724 and rs 2228611 genotypes. The linkage disequilibrium analysis of gene polymorphic loci revealed that rs 2114724–rs 2228611 was complete linkage disequilibrium, and rs 1569686–rs 2424908, rs 2424932–rs 1569696 and rs 2424932–rs 2424908 were strongly linkage disequilibrium. The polymorphisms alteration in genetic pathway may be associated with development of specific clinical features in schizophrenia.
- Open Access
- 19 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (33) , eabn7357
Loss of schizophrenia-related miR-501-3p in mice impairs sociability and memory by enhancing mGluR5-mediated glutamatergic transmission
Schizophrenia is a polygenetic disease, the heterogeneity of which is likely complicated by epigenetic modifications yet to be elucidated. Here, we performed transcriptomic analysis of peripheral blood RNA from monozygotic twins discordant for schizophrenia and identified a schizophrenia-associated down-regulated microRNA, miR-501-3p. We showed that the loss of miR-501-3p in germline knockout (KO) male mice resulted in dendritic structure defects, glutamatergic transmission enhancement, and sociability, memory, and sensorimotor gating disruptions, which were attenuated when miR-501 expression was conditionally restored in the nervous system. Combining the results of proteomic analyses with the known genes linked to schizophrenia revealed that metabotropic glutamate receptor 5 (mGluR5) was one of the miR-501-3p targets and was elevated in vivo upon loss of miR-501. Treatment with the mGluR5 negative allosteric modulator 3-2((-methyl-4-thiazolyl) ethynyl) pyridine or the N -methyl- d -aspartate receptor antagonist 2-amino-5-phosphonopentanoic acid ameliorated the deficits observed in Mir501 -KO mice. The epigenetic and pathophysiological mechanism that links miR-501-3p to the modulation of glutamatergic transmission provides etiological implications for schizophrenia.
- 19 August 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (33) , eabn7357
Open AccessLoss of schizophrenia-related miR-501-3p in mice impairs sociability and memory by enhancing mGluR5-mediated glutamatergic transmission
Schizophrenia is a polygenetic disease, the heterogeneity of which is likely complicated by epigenetic modifications yet to be elucidated. Here, we performed transcriptomic analysis of peripheral blood RNA from monozygotic twins discordant for schizophrenia and identified a schizophrenia-associated down-regulated microRNA, miR-501-3p. We showed that the loss of miR-501-3p in germline knockout (KO) male mice resulted in dendritic structure defects, glutamatergic transmission enhancement, and sociability, memory, and sensorimotor gating disruptions, which were attenuated when miR-501 expression was conditionally restored in the nervous system. Combining the results of proteomic analyses with the known genes linked to schizophrenia revealed that metabotropic glutamate receptor 5 (mGluR5) was one of the miR-501-3p targets and was elevated in vivo upon loss of miR-501. Treatment with the mGluR5 negative allosteric modulator 3-2((-methyl-4-thiazolyl) ethynyl) pyridine or the N -methyl- d -aspartate receptor antagonist 2-amino-5-phosphonopentanoic acid ameliorated the deficits observed in Mir501 -KO mice. The epigenetic and pathophysiological mechanism that links miR-501-3p to the modulation of glutamatergic transmission provides etiological implications for schizophrenia.
- Top Cited Papers
- 1 July 2020
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 87, 49-50
The differential psychological distress of populations affected by the COVID-19 pandemic
- 1 July 2020
- Published by Elsevier in Brain, Behavior, and Immunity
- Vol. 87, 49-50
Top Cited PapersThe differential psychological distress of populations affected by the COVID-19 pandemic